Katie Goldhair, MD
Ophthalmology · Golden, CONPI 1578792388
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,974 of the $9,609 with a category attached, or 83.0%. 29 manufacturers reported payments, led by Alcon at 28.7% of the total. Reporting peaked in 2020 at $2,097 and has fallen 53.6% since, to $972 in 2025. Among ophthalmology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 296 payments — averaging $32.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Sight Sciences, Inc.$2K
- Glaukos Corporation$827
- AbbVie$753
- Rxsight Inc$592
- Bausch & Lomb Americas Inc.$487
- plus $2K from 23 others
What the payments were for
- Consulting fees$1,50016%
- Food & beverage$7,97483%
- Education$1351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 75 | $2,762 |
| Sight Sciences, Inc. | 26 | $1,880 |
| Glaukos Corporation | 9 | $827 |
| AbbVie(2 entities) | 45 | $753 |
| Rxsight Inc | 6 | $592 |
| Bausch & Lomb Americas Inc. | 32 | $487 |
| Amgen(2 entities) | 9 | $387 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 23 | $287 |
| Thea Pharma Inc. | 17 | $274 |
| NEW World Medical,inc. | 7 | $202 |
| Mallinckrodt Hospital Products Inc. | 7 | $182 |
| Sun Pharmaceutical Industries Inc. | 6 | $148 |
| Ocular Therapeutix, Inc. | 5 | $116 |
| Aerie Pharmaceuticals, Inc. | 5 | $100 |
| Rayner Intraocular Lenses Limited | 1 | $93 |
| Akorn Operating Company LLC | 5 | $83 |
| Tarsus Pharmaceuticals, Inc. | 2 | $61 |
| Novartis | 3 | $57 |
| Ivantis, Inc | 3 | $54 |
| Beaver-visitec International, Inc. | 1 | $50 |
| Nova Eye, Inc. | 1 | $41 |
| Medtronic | 1 | $31 |
| Dompe US, Inc. | 1 | $25 |
| Kala Pharmaceuticals, Inc. | 1 | $22 |
| Edwards Lifesciences | 1 | $22 |
| Biotissue Holdings Inc. | 1 | $21 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
| Harrow Eye, LLC | 1 | $16 |
| Iridex Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TearCare$1,500
- RXSIGHT CONTACT LENS$361
- RXSIGHT INJECTOR CARTRIDGE$361
- RXSIGHT INJECTOR HANDPIECE$361
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$361
- Hydrus Microstent$291
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$228
- iStent inject W$186
- iDose$185
- iStent Trabecular Micro-Bypass System Model iS3$159
- Unity$146
- AcrySof IQ PanOptix UV IOL$136
- LIGHT ADJUSTABLE LENS (LAL)$134
- TEPEZZA$123
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$117
- OMNI(R) SURGICAL SYSTEM (US)$117
- AcrySof$107
How this compares
$9,609 in reported general payments places this provider in the 90th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 29 | $32,189 |
| LumiganBimatoprost | 47 | $18,048 |
| CombiganBrimonidine Tartrate/Timolol | 25 | $11,214 |
| VyzultaLatanoprostene Bunod | 11 | $9,205 |
| Prednisolone Acetate | 181 | $6,908 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 40 | $5,323 |
| Lotemax SmLoteprednol Etabonate | 21 | $5,244 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 31 | $4,810 |
| IyuzehLatanoprost/Pf | 12 | $4,032 |
| Latanoprost | 291 | $3,700 |
| TafluprostTafluprost/Pf | 21 | $3,090 |
| Brimonidine Tartrate | 102 | $2,400 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 101 | $1,121 |
| Timolol Maleate | 89 | $931 |
| Ketorolac Tromethamine | 35 | $863 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $753 | $61,451101 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $487 | $9,20511 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm | $287 | $5,24421 claims |
| Thea Pharma Inc.Iyuzeh | $274 | $4,03212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 262 ophthalmology providers in Colorado.
Other ophthalmology in Golden
- Mark PackerBoulder$3.5M
- Jon DishlerGreenwood Village$1M
- Mark DaceyDenver$370K
- Cristos IfantidesDenver$343K
- Geeta Lalchandani LalwaniBoulder$319K
- Richard DavidsonAurora$316K
- Steven DeweyColorado Springs$246K
- Jack ZamoraDenver$172K
- Eva KimDenver$95K
- Michael JansenDenver$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.